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Abstract
The number of patients requiring renal replacement therapy due to end-stage renal disease (ESRD) is increasing
worldwide. The prevalence of chronic kidney disease (CKD), and the importance of CKD as a risk factor in develop-
ment of ESRD and in complicating cardiovascular disease (CVD) have been confirmed. In recent years, the involve-
ment of angiogenesis-related factors in the progression of CKD has been studied, and the potential therapeutic
effects on CKD of modulating these factors have been identified. Vascular endothelial growth factor (VEGF)-A, a
potent pro-angiogenic factor, is involved in the development of the kidney, in maintenance of the glomerular
capillary structure and filtration barrier, and in the renal repair process after injury. VEGF-A is also involved in the
development of early diabetic nephropathy, demonstrated by the therapeutic effects of anti-VEGF-A antibody.
Angiopoietin (Ang)-1 induces the maturation of newly formed blood vessels, and the therapeutic effects of Ang-1
in diabetic nephropathy have been described. In experimental models of diabetic nephropathy, the therapeutic
effects of angiogenesis inhibitors, including angiostatin, endostatin and tumstatin peptides, the isocoumarin NM-3,
and vasohibin-1, have been reported.
Further analysis of the involvement of angiogenesis-related factors in the development of CKD is required. Deter-
mining the disease stage at which therapy is most effective and developing an effective drug delivery system tar-
geting the kidney will be essential for pro-or anti-angiogenic strategies for patients with CKD.
Introduction
The number of patients with chronic kidney disease
(CKD) progressing to end-stage renal disease (ESRD)
and requiring renal replacement therapy is increasing
worldwide. CKD currently affects over 20 million adults
in the USA and over 13 million adults in Japan [1,2]. Of
the various renal disorders predisposing to CKD, includ-
ing glomerulonephritis and hypertensive nephrosclerosis,
diabetic nephropathy is the most frequent cause of
ESRD development.
Angiogenesis - the development of new blood vessels
from pre-existing ones - is involved in physiological
events and in pathological disorders including tumor
growth and metastasis, proliferative retinopathy, rheu-
matoid arthritis, psoriasis and neointimal formation [3].
Angiogenesis is controlled by the balance between pro-
angiogenic and anti-angiogenic factors. Angiogenesis-
associated factors are involved in the development of
the kidney [4-6]. Recent experimental studies have
demonstrated the involvement of an imbalance of
angiogenesis-related factors in the progression of CKD
[7-13], and the potential therapeutic effects on CKD of
modulating these factors have been identified [14-22].
Vascular endothelial growth factor (VEGF)-A, a potent
pro-angiogenic factor, is involved in the development of
the kidney [4,5], and also plays an important role in
maintaining the glomerular capillary structure and in
the repair process following injuries of glomerular
endothelial cells and peritubular capillaries (PTC)
[14,15,17]. Physiological levels of VEGF-A are also
required for maintenance of the glomerular filtration
barrier [23]. In the early stages of diabetic nephropathy,
increases in the number of glomerular capillaries and in
the glomerular levels of VEGF-A and its receptor
VEGFR-2 are observed [10,24]. The therapeutic effects
of anti-VEGF-A strategies and anti-angiogenic factors in
diabetic nephropathy have been reported [19-21,25-30].
In this review, the biological function of angiogenesis-
associated factors in CKD and the therapeutic potential
of modulating these factors are summarized.
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growth factors in healthy kidney
A number of angiogenic growth factors are involved in
the development of the kidney and in the maintenance
of glomerular structures and the glomerular filtration
barrier function in adults. Physiological levels of angio-
genic factors such as VEGF-A and angiopoietin (Ang)-1
are crucial for maintaining intact glomerular structures
and glomerular filtration function. In some cases, protei-
nuria and endothelial dysfunction may be complicated
by excessive inhibition of these factors (for example,
treatment with anti-VEGF antibodies in patients with
malignancy). In this section, the roles of VEGF-A,
VEGFRs and other angiogenic factors including angio-
poietins in the healthy kidney are reviewed (Table 1).
VEGF-A
The role of VEGF-A in regulating angiogenesis has been
intensively investigated. VEGF-A signaling is crucially
involved in physiological and pathological angiogenesis
(for example tumor growth) [31]. The VEGF gene family
consists of VEGF-A, VEGF-B, VEGF-C and placental
growth factor (PlGF) [31]. VEGF-A is a key regulator of
blood vessel growth, whereas VEGF-C and VEGF-D are
involved in regulating lymphatic angiogenesis [32]).
Inactivation of a single Vegf allele in mice resulted in
embryonic lethality, owing to multiple developmental
anomalies including defective vascularization in several
organs, suggesting an essential role of VEGF in embryo-
nic vasculogenesis and angiogenesis [33,34]. VEGF-A
induces the proliferation of endothelial cells in vitro
[31], induces angiogenic response in vivo [35], and also
induces the survival of endothelial cells [36]. VEGF-A
affects vascular permeability [37] and promotes mono-
cyte chemotaxis [38], leading to inflammation and other
pathological consequences. VEGF-A also induces
endothelium-dependent vasodilatation, in association
with endothelium-derived nitric oxide (NO) [39]. Con-
sistent with its role in regulating vascular permeability,
VEGF-A induces fenestration of endothelial cells in
some vascular beds, including glomerular endothelial
cells [40].
Several different splice variant isoforms of VEGF-A
(VEGF121,V E G F 165,V E G F 165b,V E G F 189, VEGF206)h a v e
been reported [41-43]. The properties of native VEGF-A
(45 kDa) closely correspond to those of predominant
isoform, VEGF165 [44]. Expression of VEGF-A mRNA is
induced under hypoxic conditions in endothelial cells,
mediated through hypoxia-inducible factor (HIF)-1 [45].
In addition, growth factors such as transforming growth
factor (TGF)-a,T G F - b, [Au Query: Please check all
symbols in the paper - they did not convert properly
Answer: OK.] insulin-like growth factor (IGF)-1, platelet-
derived growth factor (PDGF) and basic fibroblast
growth factor upregulate the expression of VEGF-A
mRNA [31].
VEGF-A binds to the tyrosine kinase receptors
VEGFR-1 (also known as Flt-1) and VEGFR-2 (also
known as KDR/Flk-1) [31], and VEGF-C and VEGF-D
bind to VEGFR-3 [32]. VEGF-A also binds to a family
of co-receptors, the neuropilins [46]. VEGF165b antago-
nizes the effects of VEGF-A, and exerts anti-angiogenic
effects [43].
VEGF-A is constitutively expressed in the human kid-
ney, primarily in the glomerular visceral epithelial cells
(podocytes) and in tubular epithelial cells in the outer
Table 1 Expression and biological roles of angiogenic factors in health and CKD
Healthy kidney Human CKD (non-
diabetic)
Diabetic
nephropathy
Therapeutic effects
VEGF-A Podocyte (h, m, r),
TEC (h)
Decreased (renal) Decreased (h),
Increased (h, m,
r)
Anti-Thy1 nephritis (r), anti-GBM nephritis (r), thrombotic
microangiopathy (r), remnant kidney (r)
VEGFR-1 GEnC (h, m), PTC (h) MC (Mesangio-
proliferative GN)
NE NE
VEGFR-2 GEnC (h, m), podocyte (m),
MC (h), PTC (h)
MC (Mesangio-
proliferative GN)
Increased (r) NE
sVEGFR-1 NE Increased: pre-eclampsia,
CKD (serum)
NE Diabetic nephropathy (m)
Neuropilin-
1
GEnC (h), podocyte (h), MC
(h), TEC (m)
NE NE NE
Ang-1 podocyte (h, m) Decreased: CKD (serum) Decreased (r;
renal)
Obstructive uropathy (m), diabetic nephropathy (m)
Ang-2 TEC (m) Increased: CKD (serum) Increased (h;
serum),
increased (r, m;
renal)
NE
Ang-1 = angiopoietin-1; Ang-2 = angiopoietin-2; CKD = chronic kidney disease; GEnC = glomerular endothelial cells; GBM = glomerular basement membrane;
GN = glomerulonephritis; h = human; m = mouse; MC = mesangial cell; NE = not examined; PTC = peritubular capillaries; r = rat; TEC = tubular epithelial cells.
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in distal tubules and collecting ducts than in proximal
tubules [47,48]. VEGF-A is also expressed in mesangial
cells in vitro [49] and in disease models, but not in
mesangial cells of the healthy human kidney [47]. Podo-
cyte-specific heterozygous deletion of VEGF-A in mice
resulted in proteinuria and glomerular endothelial injury
similar to pre-eclampsia, and podocyte-specific overex-
pression of VEGF-A led to collapsing glomerulopathy,
similar to the lesions observed in HIV-associated
nephropathy [23]. Therefore, physiological levels of
VEGF-A are required for maintenance of the glomerular
filtration barrier [23]. In newborn mice, blockade of
VEGF-A with antibodies resulted in abnormal glomeruli
lacking capillary tufts and in decreased nephron num-
ber, suggesting a pivotal rolef o rV E G F - Ai nt h ed e v e l -
opment of glomerular vascular structures [4].
Transgenic rabbits expressing human VEGF165 in both
the kidney and liver exhibited proteinuria and progres-
sive renal dysfunction, with glomerular hypertrophy and
proliferation of mesangial and glomerular endothelial
cells [50]. At a later stage, these transgenic rabbits
developed microaneurysms, leading to glomerulosclero-
sis, glomerular cyst formation and tubulointerstitial inju-
ries [50]. More recently, interstitial fibrosis, tubular cyst
formation, proliferative enlargement of glomerular capil-
laries and mesangial proliferation were observed in
transgenic adult mice with tubule-specific overexpres-
sion of VEGF-A [51]. Veron et al. induced podocyte-
specific overexpression of VEGF-A in adult mice. The
authors observed proteinuria, glomerulomegaly, thicken-
ing of the glomerular basement membrane (GBM),
mesangial expansion, and podocyte injuries in these
mice, similar to the findings observed in diabetic
nephropathy [52].
In patients with cancer treated with bevacizumab, a
humanized monoclonal anti-VEGF-A antibody, throm-
botic microangiopathy developed as a complication.
Podocyte-specific deletion of VEGF-A in adult mice pro-
duced similar histological lesions [53]. Similar effects of
anti-VEGF-A strategies in healthy mice, leading to
endothelial dysfunction and proteinuria have been
reported [54]. Collectively, the physiological level of
VEGF-A is important for the maintenance of renal
structures and of an intact filtration barrier in the devel-
oping and adult kidney.
VEGF165b, an inhibitory splice variant of VEGF-A, is
produced by cultured human podocytes [55]. Denys-
Drash syndrome is a rare urogenital disorder character-
ized by male pseudohermaphroditism. It carries a high
risk for Wilms’ tumor and diffuse mesangial sclerosis,
caused by mutations affecting the zinc finger structure
of the Wilms’ tumor protein 1 [56]. Podocytes obtained
from patients with Denys-Drash syndrome express high
levels of VEGF165, but lack VEGF165b, potentially asso-
ciated with the development of glomerulosclerosis [57].
VEGFR-1 (Flt-1)
VEGF-B and PlGF do not bind to VEGFR-2, but like
VEGF-A, they do bind to VEGFR-1. Upon binding to
VEGF-A, VEGFR-1 undergoes weak tyrosine autopho-
sphorylation [58]. A soluble extracellular domain of
V E G F R - 1( s F l t - 1 )s e r v e sa saV E G Fi n h i b i t o r[ 5 9 ] .
VEGFR-1
-/- mice die in utero at embryonic days (E)8.5-
9.5, primarily due to excessive proliferation of angioblasts,
suggesting that VEGFR-1 negatively regulates the activity
of VEGF-A, at least during early development [60].
In the healthy human adult kidney, VEGFR-1 is
expressed in the endothelia of glomeruli, PTC, and pre-
and post-glomerular vessels [61,62]. In cultured mouse
podocytes under differentiation conditions, mRNA and
protein expression of VEGFR-1 have been reported [63].
In mouse glomeruli, VEGFR-1 has been detected in
endothelial cells, but not in podocytes under immunoe-
lectron microscopy [64].
VEGFR-2 (KDR/Flk-1)
VEGFR-2, a high-affinity receptor of VEGF, serves as an
important mediator of VEGF-A in inducing mitogenesis,
angiogenesis and vascular permeability [65]. VEGFR-2-
null mice die in utero, primarily due to a lack of vascu-
logenesis and failure to develop blood islands and orga-
nized blood vessels, suggesting a pivotal role for
VEGFR-2 in developmental angiogenesis and hemato-
poiesis [66]. Upon binding of VEGF-A, VEGFR-2 under-
goes dimerization and tyrosine phosphorylation, and
phosphorylates several proteins in endothelial cells such
as phospholipase C-g, phosphoinositide 3-kinase (PI3K),
Ras GTPase-activating protein and Src [67,68]. VEGF-A
induces endothelial cell proliferation by activating the
Raf-MEK-extracellular signal-regulated (ERK) pathway
[69]. Activation of VEGFR-2 prevents apoptosis of
endothelial cells through activating PI3K-Akt [36].
In the healthy human adult kidney, VEGFR-2, like
VEGFR-1 is expressed in the endothelia of glomeruli,
PTC and in pre- and post-glomerular vessels [61,62]
and weakly on mesangial cells [61,70]. No expression of
VEGFR-2, either at the mRNA or protein level, was
observed in cultured mouse podocytes under differentia-
tion conditions [63]. In mouse glomeruli, VEGFR-2 was
detected in endothelial cells and also in podocytes (loca-
lized to podocyte cell body and foot processes) by
immunoelectron microscopy [64].
Considering the dominant production of VEGF-A by
podocytes and the localization of VEGFR-2 on glomeru-
lar endothelial cells, it is possible that VEGF-A moves
across the GBM, opposing the ultrafiltration gradient to
move water and solutes from the capillaries into the
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a kinetic model for VEGF-A transport against glomeru-
lar filtration flow [71]. Owing to the size selectivity of
the slit diaphragm in the GBM, VEGF-A secreted by
podocyte foot processes accumulates in the subslit space
and generates a concentration gradient across the GBM,
resulting in the diffusion of VEGF-A from podocytes
across the GBM to the endothelial cells [71].
Neuropilin
Neuropilin is implicated in neuronal guidance, and
enhances VEGF165-mediated chemotaxis [46]. Neuropi-
lin binds to VEGF165 in an isoform-specific manner,
presenting VEGF165 to VEGFR-2 and enhancing the sig-
naling mediated by VEGFR-2 [46]. Neuropilin-1-null
mice exhibit embryonic lethality, demonstrating the role
of neuropilin-1 in the development of the vascular sys-
tem [72].
In the healthy human adult kidney, neuropilin-1 is
expressed in podocytes, mesangial cells and endothelia
of the glomeruli and the afferent arterioles [70,73]. Neu-
ropillin-1 also mediates VEGF-A-induced renal tubular
epithelial morphogenesis in mice [74].
Angiopoietins
The angiopoietin family comprises four structurally
related proteins. Ang-1, Ang-2, Ang-3 and Ang-4 [75].
Ang-1 consistently activates and tyrosine-phosphorylates
the receptor Tie-2 on endothelial cells, causing
enhanced endothelial cell survival and endothelial cell-
cell stabilization [76]. Activation of Tie-2 indirectly
recruits mesenchymal cells, probably through the action
of endothelia-derived paracrine factors, inducing attach-
ment to endothelial tube and differentiation to pericytes,
resulting in mature, ‘non-leaky’ blood vessels [77]. Ang-
2, a natural antagonist of Ang-1, loosens the attachment
of pericytes, resulting in promotion of sprouting angio-
genesis in the presence of VEGF-A [78]. When insuffi-
cient angiogenic signals are present, Ang-2 causes
endothelial cell death and vessel regression [78]. Ang-2
inhibits activation of Tie-2, and can even specifically
block Ang-1-dependent phosphorylation [78]. More
recently, activation of Tie-2 by high concentrations of
Ang-2 was reported, demonstrating the biological role
of Ang-2 not only in antagonizing Ang-1, but also in
maintaining a level of Tie-2 activation [79]. Tie-1 is
widely expressed by developing endothelia, and it down-
regulates intracellular signaling triggered by Ang-1-
induced phosphorylation of Tie-2 [80]. Mice deficient in
Ang-1 die at E12.5, exhibiting some defects in vascular
maturation [77], and mice deficient in Ang-2 die 2
weeks after birth, exhibiting some defects in retinal vas-
cularization and lymphatic function [81]. These results
indicate the crucial roles of angiopoietins during normal
vascular development in the phases of vascular differen-
tiation and maturation. During kidney development,
Ang-1, Ang-2, Tie-1 and Tie-2 are strongly expressed,
and play pivotal roles in the maturation of glomeruli
and renal blood vessels [6].
Ang-1 is expressed in nephrogenic mesenchyme, dif-
ferentiating tubular epithelia and mature podocytes in
h u m a n sa n dr o d e n t s[ 8 2 , 8 3 ] .A n g - 2i st r a n s i e n t l y
expressed in renal arterial smooth muscle and mesangial
cells during development, and is expressed in mature
tubules near the vasa rectae in mice [84]. Transgenic
mice with inducible overexpression of Ang-2 in adult-
hood, specifically in podocytes, exhibited glomerular
endothelial apoptosis and reduction in the levels of
VEGF-A and nephrin, accompanied by albuminuria [85],
suggesting that upregulation of Ang-2 may destabilize
glomerular endothelia and indirectly affect podocytes,
leading to deterioration of the glomerular filtration bar-
rier function. Expression of Ang-2 is upregulated by
hypoxia, HIF-1a, VEGF-A, angiotensin-II, leptin and
glucose in bovine microvascular endothelial cells [86].
Sonic hedgehog upregulates the expression of both Ang-
1 and Ang-2 [87]. By contrast, very little is known about
the regulatory mechanism of Ang-1.
Ephrins
The Eph family of receptor tyrosine kinases and their
corresponding ligands (ephrins) were originally identi-
fied during studies to determine embryonic patterning
and neuronal targeting [88]. EphA receptors bind to the
ephrinA ligands, and EphB receptors bind to ephrinB
ligands, with the exception of EphA4, which binds to
both ephrin types [89]. Mice deficient in ephrinB2 or
EphB4 die during embryogenesis with severe cardiovas-
cular defects, suggesting the involvement in the primary
capillary network remodeling and patterning in embryo-
nic vasculatures [90,91]. The reciprocal expression pat-
tern of ephrinB2 and EphB4 in arterial and venous
endothelial cells suggests that they might interact at the
arteriovenous interface [92]. EphA2 was observed in
tumor-associated vascular endothelial cells, ephrinA1
was detected in tumor and endothelial cells, and soluble
EhpA2-Fc exhibits anti-angiogenic and anti-tumor
effects, suggesting their involvement in tumor angiogen-
esis [93].
During mouse kidney development, ephrin-B2 is
expressed initially in a subset of podocyte progenitors
and subsequently in endothelial cells of the developing
glomerulus, while expression of EphB4 was observed in
endothelial cells of venous structures [94], suggesting
the involvement of interaction between ephrin-B2 and
EphB in glomerular microvascular assembly. In the
adult mouse kidney, mRNA for EphA1, A2, B4 and
ephrin A1 and B1 were found to be strongly expressed
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EphB6 in the tubules of the medulla and cortex [96]. By
contrast, ephrin-B1 was detected in tubules of the whole
mouse nephron [96]. In adult rat glomerulus, ephrin-B1
was found localized at the slit diaphragm, and coloca-
lized with nephrin, a key slit diaphragm protein regulat-
ing the glomerular filtration barrier [97]. The role of
ephrin-B1 on podocytes in maintaining glomerular fil-
tration barrier function has also been demonstrated [97].
Role of VEGF-A, VEGFR and other angiogenic
growth factors in CKD, both diabetic and non-
diabetic
In animal models of non-diabetic CKD including glo-
merulonephritis, glomerular endothelial cell injuries
accompany mesangial alterations or extracapillary
lesions. In these models, angiogenic stimuli are required
to promote glomerular endothelial repair in association
with accelerated resolution of nephritic alterations. In
patients in the advanced stages of glomerulonephritis or
any other type of renal disorder including hypertension-
associated nephrosclerosis and diabetic nephropathy,
glomerulosclerosis and tubulointerstitial injuries are
observed. In such cases, angiogenic stimuli may also be
required, because the rarefaction of PTC and the result-
ing tubular hypoxia worsen tubulointerstitial injuries. In
diabetic nephropathy, especially in the early stages,
excessive angiogenic signals are associated with renal
alterations and proteinuria in both humans and animals.
Therefore, the role of angiogenesis in renal disorders
may vary depending on the type and the stage of disease
(Table 1).
VEGF-A and VEGFR
In non-diabetic CKD
Proliferation of mesangial cells and expansion of mesan-
gial matrix are central features in various types of glo-
merular disorders [98,99]. In many forms of
glomerulonephritis, severe glomerular injuries are
accompanied by glomerular capillary destruction and
endothelial cell injuries. Anti-Thy-1 nephritis is one of
the widely used models of mesangioproliferative glomer-
ulonephritis [100]. Murine monoclonal 1-22-3 antibody
binds to the mesangial cell surface, causing proteinuria
and histological alterations, characterized by mesangioly-
sis followed by monocyte infiltration, mesangial cell pro-
liferation and accumulation of mesangial matrix [101].
In the early phase of rat anti-Thy-1 nephritis following
mesangiolysis, reduction in the number of glomerular
endothelial cells is observed, followed by initiation of
t h ea n g i o g e n i cg l o m e r u l a rcapillary repair process
[102,103]. The essential role of VEGF-A in promoting
glomerular capillary repair has been reported in rat anti-
Thy-1 nephritis [14,16] and in the rat anti-GBM
antibody-induced glomerulonephritis model [15]. In
addition, in this model, overexpression of soluble (s)
VEGFR-1 accelerated the progression of glomerulo-
sclerosis and interstitial fibrosis accompanied by renal
dysfunction and PTC loss [7], further supporting the
important role of VEGF-A in the maintenance and
repair of glomerular endothelia. The mechanism
involved in accelerated glomerulosclerosis in sVEGFR-1-
treated nephritic rats might involve indirect effects on
mesangial cells due to impaired repair of glomerular
endothelial cells in the presence of downregulated
VEGF-A.
Progressive loss of endothelia in glomeruli and PTC is
observed in advanced stages of CKD with renal dysfunc-
tion. Reduced or absent expression of VEGF-A was
observed in a variety of advanced CKD in humans [104].
Reduction in renal levels of VEGF-A in association with
PTC loss was also observed in animal models, including
the thrombotic microangiopathy model [18], in the rem-
nant kidney model induced by 5/6 nephrectomy [17],
and in the unilateral ureteral obstruction model [105].
Treatment with VEGF-A resulted in the recovery of
PTC number, associated with amelioration of tubuloin-
terstitial injuries in the thrombotic microangiopathy and
the remnant kidney models [17,18].
VEGFR-1 was observed in mesangial cells in biopsies
taken from patients with mesangioproliferative glomeru-
lonephritis [70]. The monocyte-macrophage lineage cells
expressed VEGFR-1, and a VEGFR-1 neutralizing mono-
clonal antibody significantly suppressed VEGF-A-
induced migration of the monocytes, suggesting the
involvement of VEGFR-1 in monocyte infiltration [106].
Pre-eclampsia remains a major cause of human mater-
nal and fetal morbidity and mortality, affecting about 5%
of pregnancies [107]. Although the precise mechanism
of this disease remains unclear, dysfunction in the
maternal vascular endothelium plays a crucial role in
the development of pre-eclampsia, resulting in hyperten-
sion and proteinuria [108]. Previous studies have sug-
gested that inadequate placental development might
lead to placental ischemia, resulting in the release of
placental factors that damage the maternal vascular
endothelium [109]. Recent reports have demonstrated
the involvement of angiogenesis-associated factors in
pre-eclampsia. Alterations in the serum level of VEGF-A
and decreases in the level of circulating PlGF in patients
with pre-eclampsia have been reported [110-112]. The
levels of sVEGFR-1, a naturally occurring antagonist of
VEGF-A, in amniotic fluid were increased in women
with pre-eclampsia [113], and increased production of
sVEGFR-1 by cytotrophoblasts isolated from women
with pre-eclampsia has been reported [114]. More
recently, increases in the level of circulating sVEGFR-1
in women with pre-eclampsia have been reported
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sVEGFR-1 levels were associated with endothelial dys-
function, suggesting that increased sVEGFR-1 levels may
predict cardiovascular risk in CKD [116].
Similarly, VEGFR-2 was found in mesangial cells in
biopsies taken from patients with mesangioproliferative
glomerulonephritis [70]. In patients with focal segmental
glomerulosclerosis, tubulointerstitial levels of neuropilin-
2 were increased, and these correlated with progressive
decline in renal function [117].
In diabetic nephropathy
Diabetic nephropathy is a complication that occurs in
30-40% of patients with type 2 diabetes, and is the most
common pathological disorder predisposing to ESRD in
Japan and in western countries [118]. Early alterations
in diabetic nephropathy include glomerular hyperfiltra-
tion, glomerular and tubular epithelial hypertrophy, and
development of microalbuminuria [119]. These early
alterations are followed by the development of GBM
thickening, accumulation of extracellular matrix (ECM)
components in mesangium and interstitium, and
increase in excretion of urinary albumin, eventually
leading to glomerulosclerosis and progressive loss of
renal function [99,120]. Involvement of angiotensin II,
IGF-I and TGF-b
1 in the development of diabetic
nephropathy has been reported [121,122].
In patients with type 1 or 2 diabetic nephropathy, histo-
logical alterations with abnormal blood vessels in the glo-
meruli have been reported [123-125]. The abnormal
vessels were seen in the glomerular capillary area, Bow-
man’s capsule and the glomerular vascular pole
[123,124,126]. Previous studies with rodent models of type
1 and 2 diabetes have demonstrated that the increased glo-
merular filtration surface in diabetic nephropathy results
from the formation of new glomerular capillaries, as well
as a slight elongation of the pre-existing capillaries
[24,127], analogous to the changes observed in pathologic
diabetic retinopathy.
Protein and mRNA level of VEGF-A and VEGFR-2
were found to be upregulated in the early and late
stages of rat experimental diabetic nephropathy [10,128].
In patients with diabetic nephropathy, plasma [129] and
urinary [130] levels of VEGF-A were elevated. In renal
biopsies from patients with diabetic nephropathy, glo-
merular levels of VEGF-A were either increased
[124,131] or decreased [132], and tubulointerstitial levels
of VEGF-A were reduced [133]. These discrepancies in
the glomerular levels of VEGF-A may be attributable to
the stage of diabetic nephropathy; that is, reduced renal
VEGF-A levels in the advanced stages of disease.
In cultured podocytes, high levels of glucose, TGF-b1
and angiotensin-II induce expression of VEGF-A [134].
VEGF-A, produced by podocytes, acts through VEGFR-
1 also located on podocytes and activates PI3K, leading
to increased production of a3(IV) collagen, a principal
component of the GBM, suggesting an autocrine role
f o rV E G F - A[ 6 3 ] .T h e s er e s u l t ss u g g e s tar o l ef o rT G F -
b1-induced endogenous VEGF-A in podocyte dysfunc-
tion, GBM thickening and alteration of the glomerular
filtration barrier in diabetic nephropathy. VEGF-A also
decreases intracellular calcium concentration, and exerts
protective effects against cytotoxic insult [135].
To address the discrepancies in function of VEGF-A
in non-diabetic CKD and diabetic nephropathy, Naka-
gawa et al. proposed the hypothesis of ‘uncoupling of
the VEGF-endothelial NO axis’ in diabetic nephropathy
[136]. Endothelial dysfunction induced by hyperglycemia
or other factors may underlie the pathogenic mechan-
isms of an elevated VEGF state. VEGF-A normally sti-
mulates endothelial NO release and acts as a trophic
factor for vascular endothelium in concert with elevated
NO levels. The increased NO derived from the endothe-
lial cells prevents excessive proliferation of endothelial
and vascular smooth muscle cells and infiltration of
monocytes/macrophages. When NO bioavailability is
reduced, as in diabetes, elevated levels of VEGF-A lead
to excessive endothelial cell proliferation, stimulation of
macrophage infiltration and activation of vascular
smooth muscle cells. Consistent with this hypothesis,
diabetes induced in endothelial NO-deficient mice
resulted in clinical and histological features identical to
human diabetic nephropathy [137]. The role of VEGF-A
in promoting macrophage infiltration through VEGFR-1
and the inhibitory effects of NO on VEGF-A-induced
macrophage infiltration were also demonstrated in dia-
betic endothelial nitric oxide synthase knockout mice
[138].
Angiopoietins
In non-diabetic CKD
Futrakul et al. reported reduction in circulating levels of
VEGF-A and Ang-1, and elevation of Ang-2 levels in
patients with CKD who had moderate to severe renal
dysfunction [139]. In a mouse model of folic acid-
induced nephrotoxicity, Ang-1 was detected in renal
arterial walls and in injured cortical distal tubules [11]. In
a mouse anti-GBM nephritis model, the glomerular level
of Ang-1 was reduced and Ang-2 was increased, in asso-
ciation with glomerular endothelial cell apoptosis [12]. In
a mouse model of unilateral ureteral obstruction, reduc-
tion in renal Ang-1 level was observed. Ang-1 gene ther-
apy in this mouse model, using an adenoviral vector
encoding a chimeric form of Ang-1 called cartilage oligo-
meric matrix protein (COMP)-Ang-1, resulted in preser-
vation of PTC and reductions in monocyte/macrophage
infiltration and interstitial fibrosis [22]. In a mouse folic
acid-induced nephrotoxicity model, adenoviral delivery
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induced inflammatory and fibrotic responses in the kid-
ney [140], suggesting that Ang-1 supplementation can
have variable outcomes on renal injuries, depending on
the disease model. Some recent studies demonstrated
that Ang-1 could have pro-inflammatory effects. Murine
macrophages expressed Tie-1 and Tie-2 in vitro [140],
neutrophils also expressed Tie-2 [141], and treatment of
aortic rings with Ang-1 upregulated chemokines [142].
In a rat angiotensin-II infusion model, renal levels of
VEGF-A, Ang-1 and Ang-2 were increased via angioten-
sin-II type 1 and 2 receptors [143]. In the same rat
model, we observed an increase in the renal Ang-1:Ang-
2 ratio, potentially counteracting VEGF-A-induced vas-
cular permeability after infusion of angiotensin-II [144].
In addition, murine macrophages express Ang-2, and
this has been implicated in the aggravation of inflamma-
tion [145]. Pharmacological blockade of the renin-angio-
tensin system ameliorated the pathological changes seen
in rat anti-Thy-1 nephritis [146]; however, infusion of
angiotensin-II before the induction of rat anti-Thy-1
nephritis unexpectedly resulted in accelerated resolution
of nephritic alterations in the early stages [147]. In the
same rat model, we observed accelerated repair of glo-
merular endothelium accompanied by renal induction of
VEGF-A signaling and increase in the Ang-1:Ang-2
ratio [148].
We have observed elevated serum Ang-2 level in
healthy pregnant women compared with non-pregnant
women, and significant suppression of circulating Ang-2
in women with pre-eclampsia [149]. The serum Ang-2
concentrations inversely correlated with proteinuria in
women with pre-eclampsia [149]. These findings suggest
an essential role for Ang-2 in placental angiogenesis
during pregnancy.
In diabetic nephropathy
In patients with type 2 diabetes, elevated circulating
levels of Ang-2 and VEGF-A were observed [150]. In a
rat model of type 1 diabetic nephropathy, decreased
renal level of Ang-1 and elevation of Ang-2 were
observed at 8 weeks after the induction of diabetes and
Ang-2 was observed in glomerular endothelia and podo-
cytes [13]. We also observed upregulation of renal Ang-
2 levels and decreased Ang-1/Ang-2 ratio accompanied
by glomerular monocyte/macrophage infiltration in
mouse type 1 and 2 diabetic nephropathy models
[25-27]. In a mouse model of obese type 2 diabetes,
Ang-1 gene therapy using adenoviral vector encoding
COMP-Ang-1 resulted in the reduction in albuminuria,
amelioration of mesangial expansion and podocyte inju-
ries accompanied by reduced monocyte/macrophage
infiltration and downregulation of chemokines and
adhesion molecules [151].
Other angiogenic factors
In a mouse model of ischemia-reperfusion injury (IRI),
renal expression of EphA2 mRNA was markedly
increased and EphA2 protein was detected in distal
tubules [95]. Interactions between EphA2 and its ephrin
ligands may be involved in cytoskeletal repair of tubular
epithelial cells in renal IRI.
PlGF, a member of VEGF family, stimulates pathologi-
cal angiogenesis through activating VEGFR-1 without
any influence on physiological processes [152]. In the
early stages (1 or 2 weeks) of the rat remnant kidney
model, renal levels of PlGF were elevated in association
with enhanced angiogenic response [153]. Whether
VEGF-A [17] or PlGF play principal roles in the angio-
genic repair process after injuries induced by renal mass
ablation needs further investigation.
Role of angiogenesis inhibitors in CKD, both
diabetic and non-diabetic
Although findings about the biological role of angiogen-
esis inhibitors in CKD are relatively limited, therapeutic
effects have been reported for angiogenesis inhibitors in
experimental diabetic nephropathy models. Angiogenesis
inhibitors exhibit therapeutic effects on diabetic nephro-
pathy by anti-angiogenic and anti-inflammatory mechan-
isms, as inhibition of excessive neovessels may reduce the
infiltration of inflammatory cells, and downregulation of
VEGF-A may ameliorate vascular permeability. However,
considering the reduction in PTC density associated with
tubular hypoxia and tubulointerstitial injuries in
advanced CKD, use of angiogenesis inhibitors may need
careful consideration.
Angiogenesis inhibitors in non-diabetic CKD
Angiostatin
Angiostatin, a proteolytic fragment of plasminogen,
potently blocks neovascularization, tumor growth and
metastasis [154]. In healthy rat kidney, angiostatin is not
expressed, but its level was enhanced in the first 3 days
after renal IRI, and remained detectable until 35 days
after induction of ischemia-reperfusion (I/R) [155].
Renal angiostatin generation after acute renal failure
induced by I/R may modulate postischemic renal capil-
lary density and thereby influence chronic renal
dysfunction.
In a rat remnant kidney model, pretreatment with
adenoassociated viral vectors encoding angiostatin
resulted in reduction in PTC density and urinary NO
levels [156]; however, in another study, interstitial fibro-
sis and monocyte infiltration was ameliorated by treat-
ment with angiostatin [156]. Therefore, angiostatin may
exert therapeutic effects in CKD through its anti-inflam-
matory actions, but potential adverse events (such as
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leading to the acceleration of tubular hypoxia/ischemia)
have to be considered.
Angiogenesis inhibitors in diabetic nephropathy
Anti-VEGF-A therapies
As described in the previous section, renal levels of
VEGF-A and VEGFR-2 were increased in both early and
late stages of rat experimental diabetic nephropathy
[10,128]. Animal studies using monoclonal anti-VEGF-A
antibodies have demonstrated the involvement of
VEGF-A in early glomerular hypertrophy and mesangial
matrix accumulation during the progressive stages of
diabetic nephropathy [19,20]. In addition, SU5416, a
pan-VEGF receptor tyrosine kinase inhibitor, reduced
albuminuria in the type 2 diabetes db/db mouse model
[21]. Podocyte-specific, doxycycline-inducible overex-
pression of sVEGFR-1 in adult mice ameliorated diabetic
glomerular injuries, further implicating the involvement
of VEGF-A in the pathogenesis of diabetic nephropathy
[64].
Tumstatin
Type IV collagen is expressed as six distinct a-chains
(a1t oa6), assembles into triple helices, and forms
organized networks. The a-chains consist of an N-term-
inal 7 S domain, a central collagenous triple helical
domain and a C-terminal globular NC1 domain.
Although the a1(IV) and a2(IV) chains are ubiquitously
distributed in human basement membranes, distribution
of the a3(IV) chain is limited to certain basement mem-
branes, such as GBM, several basement membranes of
the cochlea, and the alveolar capillary basement mem-
brane [157].
a3(IV)NC1 (also known as tumstatin, a term derived
from its unique property of causing ‘tumor-stasis’), inhi-
bits angiogenesis and tumor growth by suppression of
endothelial cell proliferation and tube formation
[158-160]. Representative matrix-derived angiogenesis
inhibitors are listed in Table 2. Tumstatin exerts its
anti-angiogenic effects by binding to avb3 integrin in an
Arg-Gly-Asp (RGD)-independent manner [161,162].
Goodpasture syndrome is an autoimmune disease
characterized by pulmonary hemorrhage and/or rapidly
progressive glomerulonephritis. The most probable dis-
ease-related pathogenic autoepitope was identified in the
tumstatin sequence [163], within the N-terminal 40
amino acids [164]. Using deletion mutants of tumstatin
and synthetic peptides, the domain possessing anti-
angiogenic properties was found to be confined to the
T3 (69-88 amino acids), T7 (74-98 amino acids) and T8
peptide regions of tumstatin, outside the Goodpasture
epitope [165,166].
Apoptosis is regulated in part at the level of protein
synthesis, and is generally associated with inhibition of
cap-dependent protein translation. Tumstatin peptides
exhibit endothelial cell-specific inhibitory effects on cap-
dependent translation by negatively regulating activation
of focal adhesion kinase (FAK), PI3K, Akt, mTOR and
eukaryotic initiation factor 4E binding protein 1 [167].
These inhibitory effects of tumstatin peptides were not
observed in b3-integrin-deficient endothelial cells,
implying an interaction of tumstatin peptides with avb3
integrin-induced negative regulatory signals counteract-
ing growth factor-initiated cell survival signals [167].
Because histological ‘angiogenic’ abnormal vessels in
the glomerular capillary area, Bowman’s capsule and the
glomerular vascular pole are observed in the early stages
of diabetic nephropathy in both humans and rodents
[24,123,124,127], and the involvement of VEGF-A was
demonstrated in the progression of experimental dia-
betic nephropathy [19,20], we hypothesized that anti-
angiogenic factors might inhibit the progression of
Table 2 Endogenous basement membrane-derived angiogenesis inhibitors
Angiogenesis
inhibitor
Parent protein Domain Receptors Inhibitory activities on EC
Endostatin a1 chain of type XVIII
collagen
NC1 Glypicans, flk-1, a 5b1-
integrin
Proliferation, migration, tube formation, survival, tumor
growth
Restin a1 chain of type XV
collagen
NC10 Unknown Proliferation, migration, tumor growth
Tumstatin a3 chain of type IV
collagen
NC1 avb3-integrin Proliferation, tube formation, survival, protein translation,
tumor growth
Arresten a1 chain of type IV
collagen
NC1 a1b1-integrin Proliferation, migration, tube formation, survival, tumor
growth
Canstatin a2 chain of type IV
collagen
NC1 a3b1-integrin Proliferation, migration, tube formation, survival, tumor
growth
a6(IV)NC1 a6 chain of type IV
collagen
NC1 Unknown Proliferation
Endorepellin Perlecan Domain
V
a 2b1-integrin Migration, tube formation, survival, blood vessel growth in
vivo
EC, endothelial cell. ECM, extracellular matrix.
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ined the therapeutic effect of tumstatin in the early
stages of diabetic nephropathy in the streptozotocin
(STZ)-induced mouse type 1 diabetes model [25]. Treat-
ment with the tumstatin T8 peptide did not affect
hyperglycemia, but significantly suppressed renal hyper-
trophy, glomerular hypertrophy/hyperfiltration and albu-
minuria, and histological alterations such as mesangial
expansion, increase in glomerular capillary number and
monocyte/macrophage infiltration in diabetic animals.
The tumstatin (T8) peptide significantly suppressed the
STZ-induced increase in VEGF-A and VEGFR-2 in the
renal cortex, suggesting that the therapeutic effect of the
tumstatin (T8) peptide in early diabetic nephropathy
may be at least partly attributable to the inhibition of
excessive activation of VEGF-A signaling, analogous to
previous studies using neutralizing anti-VEGF-A antibo-
dies [19,20]. The tumstatin (T8) peptide treatment did
not affect the renal levels of Ang1, but suppressed Ang-
2 increase in diabetic mice, leading to elevation of the
Ang-1:Ang-2 ratio [25]. The marked increase in Ang-2
over Ang-1 in diabetic mice suggests that there is a pro-
angiogenic environment, considering the simultaneous
upregulation of VEGF-A and the unstable, ‘leaky’ condi-
tion of capillaries, possibly associated with inflammatory
responses such as monocyte/macrophage recruitment.
Nephrin is a podocyte protein crucial for maintenance
of an intact glomerular filtration barrier [168]. In dia-
betic nephropathy, the protein level of nephrin decreases
in association with podocyte injury and proteinuria, and
tumstatin restored the level of nephrin, possibly asso-
ciated with its anti-albuminuric effects [25]. The indirect
influence of glomerular endothelial cells toward podo-
cytes possibly mediated via secreted factors or alteration
on matrix microenvironment, might be involved in this
mechanism.
Collectively, these results suggest that the tumstatin
peptide may have therapeutic potential in human diabetic
nephropathy, in addition to its potent anti-tumor effect.
Endostatin
Endostatin, a 20 kDa C-terminal NC1 domain of type
XVIII collagen, possesses potent anti-angiogenic activity
[169]. Endostatin was initially isolated from the condi-
tioned medium of murine hemangioendothelioma cells.
Endostatin inhibits endothelial cell proliferation, migra-
tion and tube formation in vitro [170,171], and possesses
potent inhibitory effects on tumor growth in vivo.T h e
inhibitory effects of endostatin on the expression of
VEGF in tumor cells and on vascular permeability have
been reported [172]. The therapeutic potential of endo-
statin in non-neoplastic disorders with involvement of
angiogenic processes (for example, rheumatoid arthritis,
proliferative diabetic retinopathy and peritoneal sclero-
sis) has also been reported [173-175]. The anti-
angiogenic activity of endostatin was confined to the
peptide region within the N-terminal domain [176].
Human endostatin interacts with a5b1 integrin, lead-
ing to the inhibition of the activation of FAK and subse-
quent inhibition of mitogen-activated protein kinases
(MAPKs) including ERK-1/2 and p38MAPK, resulting in
inhibition of endothelial cell migration [177]. In addi-
tion, glypicans, a form of heparan sulfate glycosamino-
glycans, bind to endostatin, and this interaction is
important for mediating the anti-angiogenic activities of
endostatin in vitro [178].
We examined the therapeutic effects of endostatin in
the early stages of diabetic nephropathy utilizing the
STZ-induced mouse type 1 diabetes model [26].
Although treatment with a synthetic endostatin peptide
encompassing the 1-27 amino acid portion of human
endostatin did not affect hyperglycemia in this model,
there was significant suppression of renal hypertrophy,
glomerular hypertrophy/hyperfiltration and albuminuria,
along with histological alterations [26]. The endostatin
peptide significantly suppressed the STZ-induced
increase in VEGF-A, VEGFR-2, Ang-2, TGF-b1, IL-6
and monocyte chemotactic protein (MCP)-1 in renal
cortex and restored the level of nephrin [26]. Because a
central involvement of a5b1i n t e g r i ni nm e d i a t i n gt h e
anti-angiogenic capacity of endostatin has been reported
[177], we studied the localization of this cell surface
receptor in diabetic mice. Although expression of a5b1
integrin was faintly present in the glomeruli of non-dia-
betic control mice, increased expression of a5b1i n t e g -
rin colocalized with CD31 was observed in the
glomeruli of diabetic mice, as detected by double immu-
nofluorescence [26]. These results suggest that the pri-
mary action of endostatin on glomerular endothelial
cells mediated via a5b1 integrin in diabetic mice. There-
fore, we speculate that endostatin indirectly affects
podocytes leading to decreased expression of VEGF-A
in diabetic mice.
NM-3
2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)
propionic acid (NM-3) is a synthetic derivative of cyto-
genin, a natural compound isolated from filtrates of
Streptoverticillium eurocidicum cultures [179]. NM-3
potently inhibits endothelial cell proliferation, migration,
sprouting and tube formation in vitro and tumor growth
in vivo [180]. Moreover, NM-3 suppresses endothelial
cell migration induced by VEGF-A, and exerts inhibitory
effects on angiogenesis in VEGF-A-secreting malignant
tumors [180]. A phase I clinical study of NM-3 in
patients with cancer has demonstrated that NM-3 has
high oral bioavailability and is a well-tolerated drug in
humans [181].
We examined the therapeutic effect of NM-3 on long-
term renal alterations in db/db mice, a model of obese
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at 8 weeks of age in db/db mice exhibiting hyperglyce-
mia and was continued until 16 weeks. Although treat-
ment with NM-3 did not affected either obesity or
hyperglycemia, significant suppression of renal hypertro-
phy, glomerular hypertrophy/hyperfiltration and albumi-
nuria, as well as histological alterations were observed in
diabetic animals [27]. NM-3 significantly suppressed the
increase in VEGF-A, Ang-2, TGF-b1 and MCP-1 seen
in the renal cortex, and restored the level of nephrin in
db/db mice [27]. The direct inhibitory effect of NM-3
on phosphorylation of VEGFR-2 in glomerular endothe-
lial cells remains to be elucidated. However, inhibitory
effects of NM-3 on renal levels of VEGF-A suggest a
potential inhibitory effect of NM-3 on the phosphoryla-
tion of VEGFR-2 in glomerular endothelial cells, result-
ing in the observed therapeutic effects of NM-3 in
diabetic mice. In vitro analysis further demonstrated the
direct inhibitory effect of NM-3 on the synthesis of
TGF-b in mesangial cells and the production of VEGF-
A in podocytes induced by high glucose [27]. These
results demonstrate the direct effect of NM-3 on mesan-
gial cells and podocytes under high glucose conditions,
in addition to its known effects on endothelial cells, and
the efficacy of angiogenesis inhibitors on long-term
renal alterations in obese type 2 diabetes.
Angiostatin
Angiostatin inhibits retinal neovascularization and
reduces retinal vascular permeability in diabetic retino-
pathy. Zhang et al. examined the potential involvement
of angiostatin in diabetic nephropathy using an STZ-
induced type 1 diabetes rat model [28]. Angiostatin
levels were dramatically decreased in the kidneys of con-
trol diabetic rats, and adenovirus-mediated delivery of
angiostatin significantly ameliorated albuminuria and
glomerular hypertrophy in diabetic rats. Inhibitory
effects of angiostatin treatment on VEGF-A and TGF-b1
in diabetic kidneys were also observed [28]. In cell cul-
ture analysis, angiostatin blocked overexpression of
VEGF-A and TGF-b1 induced by high levels of glucose,
while increasing the levels of pigment epithelium-
derived factor (PEDF), an endogenous inhibitor of dia-
betic nephropathy. Similar to NM-3, angiostatin pro-
duced direct effects on mesangial cells and endothelial
cells, as well as therapeutic effects on diabetic
nephropathy.
PEDF
PEDF is a potent inhibitor of angiogenesis, and
decreased ocular levels of PEDF are associated with dia-
betic retinopathy. Wang et al.h a v ed e m o n s t r a t e dt h a t
renal expression of PEDF was decreased in the STZ-
induced type 1 diabetic rat model, and high levels of
glucose significantly decreased PEDF secretion in pri-
mary human mesangial cells (HMC) in vitro [182].
PEDF blocked the overexpression of TGF-b and fibro-
nectin induced by high glucose levels in primary HMC
[182]. Wang et al.a l s os h o w e dt h a ta d e n o v i r a ld e l i v e r y
of PEDF into the kidney significantly ameliorated micro-
albuminuria in the early stages of diabetes by suppres-
sing TGF-b1 and connective tissue growth factor and
enhancing MMP-2, thus leading to reduced production
of ECM proteins in the diabetic kidney [29]. They
further demonstrated the anti-inflammatory action of
PEDF therapy in the same model; PEDF regulated renal
levels of intracellular adhesion molecule-1, MCP-1,
TNF-b and VEGF-A, and it also inhibited activation of
the transcription factors nuclear factor kappa B and
HIF-1 in mesangial cells [183].
Vasohibin-1
Vasohibin (VASH)-1, an endogenous angiogenesis inhi-
bitor, was identified in a microarray analysis assessing
genes upregulated by VEGF-A in endothelial cells [184].
VASH-1 serves as an endothelial cell-derived negative
feedback regulator of angiogenesis, and its therapeutic
efficacies on tumor growth, atherosclerosis and prolif-
erative retinopathy models have been reported
[184-186]. The potential of VASH-1 as a biomarker of
disorders associated with angiogenesis was demonstrated
for endometrial cancer and rheumatoid arthritis
[187,188]. We recently reported the therapeutic effects
of VASH-1 in the mouse STZ-induced type 1 diabetic
nephropathy model [30]. Mice were given intravenous
injections of adenoviral vectors encoding VASH-1
(AdhVASH-1) every 2 weeks. Treatment with
AdhVASH-1 resulted in sustained increase in the circu-
lating levels of VASH-1, and significantly suppressed
renal and glomerular hypertrophy, glomerular hyperfil-
tration, albuminuria, increase in the CD31+ glomerular
endothelial area and F4/80+ monocyte/macrophage infil-
tration, and accumulation of type IV collagen and
mesangial matrix compared with AdLacZ-treated dia-
betic mice at 4 weeks after initiating treatment [30].
Interestingly, VASH-1 treatment did not affect the
microvascular density of PTC in diabetic animals.
Increase in the renal levels of TGF-b1, MCP-1 and
RAGE (receptor for advanced glycation end products) in
diabetic animals was significantly suppressed by
AdhVASH-1. VASH-1 further suppressed increase in
TGF-b1, MCP-1 and RAGE induced by high glucose
levels in cultured mouse mesangial cells. Increased
phosphorylation of VEGFR2 was suppressed in the kid-
neys of AdhVASH-1-treated diabetic animals and in cul-
tured glomerular endothelial cells [30]. Endogenous
mouse VASH-1 was localized to the mesangial and
endothelial areas in glomeruli of diabetic mice. These
results suggest therapeutic potential for VASH-1 in
treating early diabetic nephropathy thought to be
mediated via glomerular endothelial and mesangial cells
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effects of VASH-1 on glomerular podocytes, possibly
associated with anti-albuminuric effect (manuscript in
submission).
Levels of endogenousVASH-1 are decreased in prolif-
erating endothelial cells at the sprouting front, but are
elevated in non-proliferating endothelial cells at the ter-
mination zone of angiogenesis, presumably serving to
halt angiogenesis [189]. VASH-2, a homologue of
VASH-1, was identified subsequently, and is mainly
derived from infiltrating mononuclear cells mobilized
from bone marrow, which infiltrate the sprouting front.
Levels of endogenous VASH-2 are elevated at the
sprouting front, but are low at the termination zone of
angiogenesis, presumably serving to induce angiogenesis
[189]. Exogenous VASH-1 inhibited angiogenesis at the
sprouting front, where endogenous VASH-1 was scarce,
but did not influence vascularity in the termination
zone, where endogenous VASH-1 was high [189]. Exo-
genous VASH-2 prevented the termination of angiogen-
esis, and increased vascularity in the termination zone
[189]. Angiogenesis was persistent in the termination
zone in VASH-1 knockout mice, but was deficient at
the sprouting front in VASH-2 knockout mice [189].
Regulation of the balance between VASH-1 and VASH-
2 may be involved in angiogenesis and vascular matura-
tion, and may be involved in the progression and the
control of CKD (Figure 2).
Potential problems in using anti-angiogenic therapies in
patients with CKD
The potential adverse events of bevacizumab, a huma-
nized monoclonal antibody against VEGF-A have been
reported in patients with cancer, with administration of
the drug resulting in thrombotic microangiopathy [53].
The lack of such histological alterations in previous
experimental diabetic nephropathy models treated with
anti-VEGF antibodies or SU5416 [19-21], and ameliora-
tion of diabetic glomerular alterations by inducible
podocyte-specific overexpression of sVEGFR-1 in adult
mice [64] suggest that anti-VEGF-A therapy might not
be detrimental for patients with diabetic nephropathy.
In fact, systemic delivery of sVEGFR-1 resulted in the
protection of podocytes and a reduction in albuminuria,
but exacerbated tubulointerstitial injuries accompanied
by PTC loss in db/db mice [190]. Although tumstatin,
endostatin, NM-3 and VASH-1 suppress overactivation
of VEGFR-2, they do not serve as specific inhibitors of
VEGF-A signaling, unlike bevacizumab or other specific
anti-VEGF-A therapeutics. Because PTC loss, chronic
Figure 1 Mechanisms of action of vasohibin (VASH)-1 in diabetic nephropathy. (A) Mechanisms involved in the progression of diabetic
nephropathy. (B) Exogenous VASH-1 suppresses renal alterations in the experimental mouse type 1 diabetes model through anti-angiogenic,
anti-inflammatory and anti-fibrotic effects and also through protecting podocytes. VASH-1 suppresses excessive activation of VEGF-A signaling on
glomerular endothelial cells, and also exerts direct effects on mesangial cells and podocytes in diabetic environments [30]. AGE = advanced
glycation end-product; Ang-II = angiotensin-II; ESRD = end stage renal disease; GBM = glomerular basement membrane; MM = mesangial matrix;
PKC = protein kinase C; TGF-b = transforming growth factor-b.
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progression of CKD [191], careful evaluation of patients’
long-term outcome after anti-angiogenic therapeutics is
required.
In the advanced stages of CKD including diabetic
nephropathy, anti-angiogenic reagents may impair neo-
vessel formation, leading to deterioration of macrovas-
cular complications such as myocardial infarction and
limb ischemia. Thus, considering the involvement of
angiogenesis in atherosclerosis., anti-angiogenic thera-
peutics might be tolerable or even therapeutic for ather-
osclerotic conditions. In fact, the therapeutic effects of
VASH-1 in preventing neointimal formation have been
reported [185]. In addition, VASH-1 does not impair
healthy blood or lymphatic vessels in mice [192], sug-
gesting relative safety of this factor in treating patients
with diabetic and non-diabetic CKD. Regarding the
question of using adenoviral vectors to treat patients
with diabetes, potential adverse events such as non-spe-
cific inflammatory reactions and the replication of ade-
noviruses in vivo must be avoided, and further
assessments on the safety of this strategy are required.
Conclusion
We have looked at recent advances on the involvement
of angiogenic and antiangiogenic factors in CKD and
potential experimental approaches using angiogenesis
inhibitors to treat CKD, including diabetic nephropathy.
Based on the mechanistic insight into the involvement
of angiogenesis in CKD, use of novel therapeutic
reagents in patients with CKD in clinical practice is
expected in the near future, leading to the eventual
reduction in the number of patients developing ESRD.
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Figure 2 Regulation of angiogenic process by endogenous VASH-1 and VASH-2. Levels of endogenous VASH-1 are decreased in
proliferating endothelial cells at the sprouting front, but elevated in non-proliferating endothelial cells at the termination zone of angiogenesis,
presumably serving to halt angiogenesis (189). Levels of endogenous VASH-2, a homologue of VASH-1 that is mainly derived from infiltrating
mononuclear cells, are elevated at the sprouting front, but low at the termination zone of angiogenesis, serving to induce angiogenesis (189).
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